Precision BioSciences will present new biopsy data from its Phase 1 ELIMINATE‑B trial at the European Association for the Study of the Liver (EASL) Congress on May 27, 2026, in a late‑breaking poster session.
The ELIMINATE‑B study is the company’s first‑in‑human gene‑editing program that uses its proprietary ARCUS platform to target and eliminate hepatitis B virus cccDNA, the root cause of chronic infection. The data presentation marks a key step in the trial’s development timeline, providing the scientific community with early evidence of the therapy’s safety and potential efficacy.
Precision’s 2025 financial results underscore the company’s growing commercial momentum: revenue rose to $34.2 million from $0.6 million in 2024, driven largely by agreements with Novartis and Imugene. Cash, cash equivalents, and restricted cash totaled $137.2 million at the end of 2025, giving the company a runway through 2028 to fund its clinical and development programs.
In March 2026, CEO Michael Amoroso highlighted the company’s progress, noting that 2025 was an “exceptional year marked by meaningful clinical and financial progress” and that the company was positioned for success in 2026 and beyond.
The presentation is expected to demonstrate progress toward regulatory milestones, attract payers and partners, and potentially accelerate market entry for PBGENE‑HBV. The program already holds FDA Fast Track designation, and the new data will inform future regulatory submissions and partnership discussions.
The EASL Congress will be held in Barcelona, Spain, from May 27‑30, 2026, with the late‑breaking poster scheduled for the opening day on May 27. The event represents a significant milestone for Precision’s pipeline and could influence investor perception of the company’s trajectory.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.